Philippe Pouletty (Credit: Deinove)

No pain, no gain: Com­pa­ny-build­ing French VC scores €250M for life sci­ences fund

In the Truf­fle Cap­i­tal play­book, you ei­ther go big or go home.

The French VC firm does not both­er with pitch­es from com­pa­nies vy­ing for in­vest­ment — in­stead, it sources the raw ma­te­r­i­al to build com­pa­nies from scratch. On Wednes­day, it un­veiled a €250 mil­lion boost to in­vest in the life sci­ences, in par­tic­u­lar, the realm of in­ter­ven­tion­al med­ical de­vices.

The recipe for in­vest­ment is ar­du­ous. The firm ap­prais­es about 1000 un­pub­lished patent ap­pli­ca­tions from the top 50 uni­ver­si­ties across the Unit­ed States and Eu­rope. Af­ter whit­tling the list to five per year, it goes about ne­go­ti­at­ing ex­clu­sive glob­al li­cens­es.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.